Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Core Viewpoint - Kymera Therapeutics reported a quarterly loss of $0.82 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.83, and an improvement from a loss of $0.90 per share a year ago [1][2] Financial Performance - The company posted revenues of $3.74 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 58.27%, compared to $4.73 million in revenues a year ago [2] - Over the last four quarters, Kymera Therapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - Kymera Therapeutics shares have increased approximately 87.2% since the beginning of the year, outperforming the S&P 500's gain of 21.9% [3] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.78 on revenues of $13.41 million, and for the current fiscal year, it is -$2.85 on revenues of $58.33 million [7] - The estimate revisions trend for Kymera Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Kymera Therapeutics belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]